| (Values in U.S. Thousands) | Mar, 2024 | Dec, 2023 | Sep, 2023 | Jun, 2023 | Mar, 2023 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | -100.00% |
| Net Income | -8,830 | -9,130 | -8,300 | -8,360 | -10,010 |
| Net Income Growth | +3.29% | -10.00% | +0.72% | +16.48% | -8.10% |
Effector Therapeutics Inc (EFTR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
eFFECTOR Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs referred to as STRIs. eFFECTOR Therapeutics Inc., formerly known as Locust Walk Acquisition Corp., is based in SAN DIEGO.
Fiscal Year End Date: 12/31